IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation

Figure 6 IL-22 promotes the progression of cholangiocarcinoma in in vivo experiments. A: HE staining of liver tissue in rats administered thioacetamide for different weeks; B: Gross specimen images of liver tissues from negative control group, experimental group A, and experimental group B; C: Representative images of subcutaneous tumor samples in nude mice xenografts, with statistical analysis of tumor weight and tumor volume among samples. ^aP < 0.01, ^bP < 0.001. NC: Negative control; TAA: Thioacetamide.